BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy

Source: OncLive, December 2021

The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.

The addition of BO-112 to pembrolizumab (Keytruda) produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial (NCT04570332) presented during the 2021 SITC Annual Meeting.

Of 37 patients who were evaluable for response, the combination elicited an objective response rate (ORR) of 27%; 2 patients achieved a pathologic complete responses (CRs) by week 8. Moreover, 37.8% of patients (n = 14) had stable disease at week 8, which translated to a disease control rate (DCR) of 64.9%. All responders experienced a higher tumor size reduction.